|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All
Recent | 14: | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Drug, bio-affecting and body treating compositionsBelow are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 10/02/2014 > 291 patent applications in 128 patent subcategories.
20140294722 - Anti-pancreatic cancer antibodies: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to... Agent:
20140294723 - Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and/or their cancerous counterpart: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.... Agent: Philogen S.p.a.
20140294724 - Compositions and methods for treatment of proteinopathies: This invention relates to antibody drug conjugates and methods of use thereof. More particularly, antibody drug conjugates comprising a cytoprotective agent are provided, wherein the conjugates are useful for the treatment of proteinopathies such as Alzheimer's disease.... Agent: Intellect Neurosciences, Inc.
20140294725 - Uses of labeled hsp90 inhibitors: The invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor. The disclosure provides a method for determining whether a tumor... Agent: Sloan-kettering Institute For Cancer Research
20140294726 - Methods for diagnosing and treating alzheimer's disease by administering an anti-angiogenic agent: Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the... Agent:
20140294727 - Peptides for assisting delivery across the blood brain barrier: The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The compositions and methods are useful for delivering agents across the blood-brain barrier. The present invention also provides methods of using the... Agent: Children's Medical Center Corporation
20140294730 - Compositions and methods for diagnosing and monitoring ovarian cancer progression and treatment: The present invention provides compositions and methods useful for diagnosing, monitoring the progression, identifying the location, and monitoring the treatment response in ovarian cancer based on detecting and locating VCAM-1 expression.... Agent: University Of Virginia Patent Foundation
20140294732 - Early diagnostic of neurodegenerative diseases: The present application provides a method for diagnosing a neurodegenerative disease in a subject at risk of having said neurodegenerative disease, said method comprising the steps of a) having said subject at risk of having said neurodegenerative disease perform a series of fast, brief and powerful movements that recruit fast-fatigable... Agent: Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute
20140294729 - Methods for identification and use of agents targeting cancer stem cells: The invention relates to methods for identifying compounds and compositions that target cancer stem cells. In some aspects, the invention relates to treatment methods that use compounds and compositions that specifically target cancer stem cells for inhibiting the growth and/or survival of cancer stem cells in a subject in need... Agent: President And Fellows Of Harvard College
20140294731 - Phosphospecific antibodies recognising tau: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods... Agent:
20140294728 - Systems and methods for detecting efforts to thwart material detection by service animals: Methods and systems for detecting efforts to thwart the sense of smell of service animals and sniffer dogs. Methods and systems for detecting the introduction of and for neutralizing the effects of ONM introduced into an area. Methods and systems for the controlling the direction of the emission or ONM... Agent:
20140294733 - Multifunctional small molecules: The present invention relates to dendrimer synthesis. Specifically, the present invention relates to dendrimer compositions (e.g., scaffolds) capable of copper-free click conjugation for use in the synthesis of functionalized dendrimers, and methods of use of the same.... Agent:
20140294734 - Magnetic resonance imaging (mri) based quantitative kidney perfusion analysis: Example apparatus and methods provide improved spatial and temporal resolution over conventional magnetic resonance renography (MRR). Example apparatus and methods reconstruct under-sampled three-dimensional (3D) data associated with nuclear magnetic resonance (NMR) signals acquired from a kidney. The data is reconstructed using a 3D through-time non-Cartesian generalized auto-calibrating partially parallel acquisitions... Agent:
20140294735 - Polymer-type fluorescent molecule probe: The present invention provides a fluorescent molecular probe for efficient fluorescent detection (visualization) of tumors or for implementing fluorescent detection and photodynamic treatment, more specifically, the present invention provides a macromolecular fluorescent molecular probe for fluorescent detection of tumor, comprising a complex comprising a fluorescent molecule and a biocompatibie macromolecule.... Agent:
20140294736 - Toothpaste: A dental brushing composition including a brushing composition base additionally containing a plurality of microparticles, the particles comprising a core, a coating essentially completely surrounding the core, and two different flavors, a general flavor and an indicator flavor, the general flavor being in the coating and the indicator flavor in... Agent: Givaudan S.a.
20140294737 - Treatment of rhinitis: The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a danazol compound or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical product formulated for nasal administration. The product comprises a danazol compound or a pharmaceutically acceptable salt thereof.... Agent:
20140294738 - Treatment of rhinitis: The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP) formulated for nasal administration. The invention also provides a pharmaceutical product comprising a DA-DKP containing composition.... Agent: Ampio Pharmaceuticals, Inc.
20140294739 - Compositions containing zinc salts and isothiocyanates for reduction of oral volatile sulfur compounds (vscs): Combinations of a zinc salt and an isothiocyanate are provided, and more particularly to a consumer acceptable oral composition containing such combination which is effective in the reduction of volatile sulfur compounds (VSCs).... Agent: Wm. Wrigley Jr. Company
20140294742 - Anti-plaque dental compositions: Anti-plaque dental treatment compositions are useful in treating and/or preventing formation of dental plaque and biofilm. The anti-plaque compositions are configured for daily application to a patient's teeth in order to inhibit dental plaque formation and generally include a peroxide-based anti-bacterial compound, xylitol in an amount so as to provide... Agent:
20140294741 - Enamel protectant and repair toothpaste treatments: Substantially aqueous-free, enamel protectant and enamel repair toothpaste treatments containing: stannous fluoride, calcium and a substantivity agent comprising: an emulsion of polydimethylsiloxane in a nonionic surfactant, wherein: (a) substantivity of said stannous fluoride and calcium into biofilm present on enamel is enhanced through calcium binding shifting from bidentate to monodentate... Agent: Premier Dental Products Company
20140294740 - Oral care compositions: Described herein are compositions comprising a low abrasive silica and a fine silica thickener, and suspended elements, along with methods for making and using the same.... Agent: Colgate-palmolive Company
20140294743 - Cosmetic and/or dermatological composition containing a merocyanine derivative comprising specific polar groups consisting of hydroxyl- and ether-functionalities: The present invention relates to a cosmetic and/or dermatological composition comprising in a physiologically acceptable medium at least one merocyanine derivative of formula (1) or (2) and/or its E,E-, E,Z- or Z,Z-geometrical isomer forms: comprising specific polar groups consisting of hydroxyl- and ether-functionalities. Another object of the present invention relates... Agent: L'oreal
20140294744 - Alkyl ketal esters as dispersants and slip agents for particulate solids, methods of manufacture, and uses thereof: wherein a is 0 or an integer of 1 to 12, specifically 1 to 6, more specifically 1 to 4; b is 0 or 1; R2 is a divalent C1-8 group optionally substituted with up to 5 hydroxyl groups; and R1 is C1-6 alkyl, and wherein at least a portion... Agent: Segetis, Inc.
20140294745 - Coral extract for skin whitening, moisture retention, elasticity improvement, anti-inflammation and occlusion of wounds and extracting method thereof: A coral extract for skin whitening, moisture retention, elasticity improvement, anti-inflammation and occlusion of wounds and its extracting method is provided. The coral extract is extracted from Briareum excavatum. The extracting method comprises: extracting with organic solvents, partitioning with water and ethyl acetate and separating via column chromatography. The coral... Agent: Uni-president Biotech Co., Ltd.
20140294746 - Aminofunctional silicone emulsions: Aqueous silicone emulsions are disclosed comprising: A) an aminofunctional organopolysiloxane, B) a quaternary ammonium surfactant having a formula R1 R2 R3 R4 N+ X−, where R1 is an organofunctional group containing at least 10 carbon atoms, R2 is R1 or a hydrocarbyl containing 1 to 12 carbon atoms, R3 is... Agent:
20140294747 - Hair therapy product containing no arylated silicones: A hair treatment medium having the absence of arylated silicones includes a) at least one diester of the propylene glycol according to the formula (I), in which R and R denote, independently of one another, a residue selected from at least one linear, saturated or unsaturated, branched, saturated or unsaturated... Agent:
20140294748 - Hair treatment without arylated silicones: A hair treatment medium including diesters of propylene glycol and protein hydrolysates in the absence of arylated silicones includes at least one diester of the propylene glycol according to the formula (I), in which R1 and R2 denote, independently of one another, a residue selected from at least one linear,... Agent:
20140294749 - Water soluble antimicrobial composition: The present invention provides for antimicrobial compositions, methods of preparing the antimicrobial compositions, methods of using the antimicrobial compositions, and/or kits that include the antimicrobial compositions. The antimicrobial compositions can be in a dry, solid (e.g., powdered) form, or can be in a liquid (e.g., aqueous) form.... Agent: Medivators Inc.
20140294750 - Aqueous pharmaceutical compositions containing borate-polyol complexes: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate, a preservative or both.... Agent:
20140294751 - Hemocompatibility modifiers for cross-linked polymeric material: The invention concerns methods of treating blood, blood product, or physiologic fluid to provide at least one of (i) increasing shelf life of the blood, blood product or physiologic fluid, (ii) maintaining freshness of new blood, blood product or physiologic fluid, and (iii) removing undesirable molecules from the blood, blood... Agent: Cytosorbents Corporation
20140294752 - Method for nucleic acid delivery using hyaluronic acid: A hyaluronic acid conjugates including hyaluronic acid, a disulfide bond-containing crosslinking agent, and a cationic, amphiphilic polymer; a hyaluronic acid-nucleic acid complex in which a nucleic acid is bound to the hyaluronic acid conjugate; a composition in which the hyaluronic acid-nucleic acid complexes are crosslinked with each other; a nucleic... Agent: Samsung Electronics Co., Ltd.
20140294756 - Long-term storage of non-glycosylated recombinant human g-csf: The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing the non-glycosylated recombinant human G-CSF and sorbital is cooled to a temperature of −15° C. or below to obtain a frozen G-CSF composition, which frozen... Agent: Sandoz Ag
20140294755 - Materials and methods relating to stem cell mobilization by multi-pegylated granulocyte colony stimulating factor: The present invention relates to the use of multi-PEGylated granulocyte colony stimulating factor (G-CSF) preparations to mobilize hematopoietic stem cells.... Agent: Amgen Inc.
20140294753 - Novel use of ganodermic acids for treating cancer: Novel Uses of a small molecule, ganodermic acid S (GMAS), are disclosed herein. The GMAS is useful as a lead compound for manufacturing a medicament or a pharmaceutical composition for treating cancer, including metastatic or drug-resistant cancer, in a patient.... Agent: Double Crane Biotechnology Co. Ltd
20140294757 - Stabilisation of polypeptides: A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof;... Agent: Stabilitech Ltd.
20140294754 - Use of tumor fas expression to determine response to anti-cancer therapy: The invention provides methods for using expression levels of Fas to select individuals or subpopulation of individuals who can benefit from an anti-cancer therapy and for assessing whether an individual suspected of having or developing cancerous tumors will beneficially respond to an anticancer therapy. The invention additionally provides methods of... Agent:
20140294764 - Compounds and compositions used to epigenetically transform cells and methods related thereto: This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, the disclosure contemplates inducing cells,... Agent: Emory University
20140294762 - Glycopegylation methods and proteins/peptides produced by the methods: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.... Agent: Novo Nordisk A/s
20140294758 - Light chain immunoglobulin fusion proteins and methods of use thereof: Provided are recombinant antibodies comprising one or more peptides fused to the C-terminus of the light chain constant region. Recombinant immunocytokines comprising a cytokine fused to the C-terminus of the light chain constant region are described and shown to be surprisingly active.... Agent:
20140294765 - Lsr antibodies, and uses thereof for treatment of cancer: This invention relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LSR molecules, which are suitable drugs for immunotherapy and treatment of specific cancer.... Agent: Compugen Ltd.
20140294760 - Novel cell and therapeutical and diagnostical methods based thereon: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening... Agent: Faron Pharmaceuticals Oy
20140294763 - Peptidomimetic protease inhibitors: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds... Agent:
20140294759 - Targeting regulatory t cells with heterodimeric proteins: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.... Agent:
20140294761 - Treatments for migraine and related disorders: Embodiments are directed to compositions and methods of treating migraine and related neurological disorders. In certain aspects, methods and compositions are for reducing cortical spreading depression and/or suppressing the neurochemical basis for chronic and acute migraine events, and provide methods and pharmaceutical compositions related to both acute and preventive therapies... Agent: The University Of Chicago
20140294766 - Anti-infective agents and uses thereof: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts,... Agent:
20140294767 - Method of treating hcv infection with a small molecule chk2 inhibitor: A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: G1 is a group of the formula or where n is 0, 1,... Agent:
20140294769 - 2',4'-fluoro nucleosides for the treatment of hcv: m
20140294768 - Responsiveness to angiogenesis inhibitors: The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such... Agent:
20140294770 - Compositions and methods for spinal disc repair and other surgical and non-surgical indications: The present invention features, inter alia, biocompatible compositions that include a poloxamer and one or more additives such as hyaluronic acid, gelatin, fibronectin, or a peptide fragment of fibronectin. The compositions are useful in tissue repair or remodeling, including repair of an injured spinal disc, in drug delivery, in cell... Agent: The Research Foundation Of State University Of New York
20140294771 - Adeno-associated virus virions with variant capsid and methods of use thereof: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and... Agent: The Regents Of The University Of California
20140294772 - Thymidine kinase diagnostic assay for gene therapy applications: Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.... Agent: Epeius Biotechnologies Corporation
20140294786 - Alimentary protein-based scaffolds (aps) for wound healing, regenerative medicine and drug discovery: The invention provides engineered biomaterials derived from plant products. The engineered biomaterials are useful for biomedical applications. The engineered biomaterials are able to support the growth of animal calls.... Agent:
20140294784 - Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same: Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer... Agent: Thomas Jefferson University
20140294785 - Dosage compensating transgenes and cells: Methods and compositions for reducing expression of genes on Chromosome 21 (“Chr 21”) by targeting an XIST transgene to the Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) gene or a Regulator of calcineurin 1 (RCAN1) gene, and cells and transgenic animals comprising an XIST transgene inserted into a DYRK1A or RCAN1... Agent: University Of Massachusetts
20140294774 - Method for preventing and/or treating insulin resistance: Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus,... Agent: Academisch Medisch Centrum
20140294773 - Modified cascade ribonucleoproteins and uses thereof: A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or... Agent:
20140294787 - Extensional viscosity to promote safe swallowing of food boluses: Nutritional products having improved cohesiveness of food boluses and methods of making and using same are provided. The nutritional products may include nutritional compositions and high molecular weight, water-soluble polymers such that the nutritional products have extensional viscosities that provide improved cohesiveness to the nutritional products and Trouton ratios of... Agent:
20140294788 - Methods for enhancing muscle protein synthesis following concurrent training: The present disclosure provides methods for enhancing muscle protein synthesis following physical exertion. In a general embodiment, a method for enhancing muscle protein synthesis following physical exertion is provided and includes administering to an individual a composition comprising from about 15 to about 35 g protein immediately following concurrent training.... Agent: Nestec S.a.
20140294789 - Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract: Disclosed are nutritional compositions including galactooligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, children, and adults for preventing injury and/or improving the healing of the gastrointestinal tract. Additional suitable methods of using the nutritional compositions including the galactooligosaccharides are also disclosed.... Agent: Abbott Laboratories
20140294791 - Lactobacillus paracasei subsp. paracasei, as an agent for inhibiting listeria monocytogenes in vivo infection: The present invention relates to the use of the probiotic strain of Lactobacillus paracasei subsp. paracasei deposited at the CNCM under the reference I-3689, for inhibiting in vivo infection by Listeria monocytogenes.... Agent: Compagnie Gervais Danone
20140294790 - Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend: A method and composition prevents, controls and ameliorates urinary tract infections caused by E. coli by administering a therapeutically effective amount of a human dietary supplement composition comprising a cranberry derivative or proanthocyanidin containing concentrate, D-mannose and a proprietary probiotic blend. The cranberry derivative or proanthocyanidin containing concentrate comprises from... Agent:
20140294780 - Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators: The present disclosure provides methods and compositions, including a placental extract, for inducing and/or modulating angiogenesis; methods of identifying modulators of angiogenesis, and assays for identifying modulators of angiogenesis. The present disclosure also provides methods of making a composition, including a placental extract that can induce and/or modulate angiogenesis.... Agent:
20140294777 - Immunocompatible amniotic membrane products: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product... Agent: Osiris Therapeutics, Inc.
20140294783 - Implantable scaffolds and methods of use: Inventive concepts relate general to the field of implantable three-dimensional scaffolds. More particularly, methods of preparing and using implantable nanofibrous tissue scaffolds are described. Inventive scaffolds can be used for treatment of defects in a living organism, such as hard or soft tissue defects including bone.... Agent:
20140294776 - Isolated populations of female germline stem cells and cell preparations and compositions thereof: The present invention relates to female germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.... Agent:
20140294781 - Method to formulate t-cells: A method for formulating T-cells for use as a medicant comprises suspending T-cells with cross-linked surface moieties in a media suitable for infusion. The cross-linked T-cells are packaged in a container suitable for administration to a patient.... Agent:
20140294775 - Methods for treating obesity and/or metabolic syndrome: The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.... Agent: Mesoblast, Inc.
20140294779 - Modalities for the treatment of degenerative diseases of the retina: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.... Agent: Advanced Cell Technology, Inc.
20140294778 - Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.... Agent: Advanced Cell Technology, Inc.
20140294782 - Reprogramming of cellular adhesion: Disclosed are membrane-anchored polynucleotides, and compositions comprising the membrane-anchored polynucleotides. Also disclosed are the processes for the synthesis of these compounds, compositions comprising such compounds, and the use of such compounds and compositions in research and therapeutic applications.... Agent:
20140294793 - Gpr15-mediated homing and uses thereof: The present invention is directed to in vitro methods for promoting expression of G-protein coupled receptor 15 (GPR15) on T cells, GPR15+ enriched populations of T cells generated using these methods and compositions thereof, as well as methods of using these T cell populations for therapeutic purposes.... Agent:
20140294792 - T-reg cell expansion: This invention relates to methods of expanding T regulatory cells through OX40L and Jagged-1 induced signaling. The methods can be used for treating autoimmune diseases.... Agent: The Board Of Trustees Of The University Of Illinois
20140294794 - Methods for treating bleeding disorders using a platelet subpopulation: The present invention relates to a platelet subpopulation with high binding capacity to recombinant activated factor VII (rFVIIa), and its use for the treatment of bleeding disorders and for determining whether a subject is a candidate for treatment with rFVIIa.... Agent: Baxter International Inc.
20140294796 - Aromatic-cationic peptides and uses of same: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.... Agent:
20140294795 - Nutritional composition: The present invention provides nutritional compositions that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering... Agent:
20140294797 - Non-cytotoxic protein conjugates: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the... Agent:
20140294798 - Rbap48 transgenic mice for drug discovery in age-related memory decline: Described is a transgenic mouse with two transgenes, each of which transgene comprises a DNA sequence encoding a dominant negative form of RbAp48 protein, wherein the expression of the dominant negative form of RbAp48 is spatially restricted to the forebrain by a CaM Kinase IIa promoter and wherein the expression... Agent: The Trustees Of Columbia University In The City Of New York
20140294799 - Use of compositions having a low polyamine content in the prevention or treatment of adverse effects linked to cancer treatment: The composition includes, per gram of composition, less than 600, in particular less than 400 picomoles of biologically active polyamines, for use in the prevention or treatment of radiotherapy-induced pathologies of the skin or mucous membranes in a patient, in particular a human or an animal.... Agent: Nutrialys Medical Nutrition Sa
20140294800 - Method of characterizing lysosomal enzymes: The present invention provides, among other things, methods for the characterization of recombinant Heparan N-Sulfatase (HNS) during manufacture. The present invention uses capillary zone electrophoresis to determine the charge profile, isoform distribution, and/or glycan profile of recombinant HNS; and represents a quality feature for the batch consistency, storage stability, biological... Agent: Shire Human Genetic Therapies, Inc.
20140294802 - Methods and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase: The invention relates to methods and compositions for reducing serum levels of triacylglycerides in human subjects. In particular, the invention relates to the oral administration of an effective amount of a fungal lipase formulation, to a human subject having borderline-high or high serum levels of triacylglycerides, for a time period... Agent: Bio-cat, Inc.
20140294801 - Sequence-specific mrna interferase and uses thereof: The present invention provides an improved and specific mRNA interferase and related methods of protein-based mRNA interference.... Agent: Rutgers, The State University Of New Jersey
20140294803 - Methods for treating headache: A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the... Agent: Allergan, Inc.
20140294804 - Methods of treating pain: The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity.... Agent: Saint Louis University
20140294809 - Anti-alpha(v)beta(6) antibodies and uses thereof: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αvβ6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of... Agent: Biogen Idec Ma Inc.
20140294819 - Canine/feline cd20 binding epitope and compositions for binding thereto: The present invention provides acyclic polypeptide fragment of CD20 comprising (i) a contiguous amino acid sequence consisting of amino acid residues SEKNS (SEQ ID NO:67); (ii) a first cysteine residue which is present at a region N-terminal to the contiguous amino acid sequence and (iii) a second cysteine residue which... Agent:
20140294815 - Caninised tumour necrosis factor antibodies and methods of using the same: Caninised and chimeric antibodies and antigen binding fragments thereof which bind specifically to canine tumour necrosis factor and inhibit the ability of canine TNF to bind to the TNFR1 receptor are provided. The invention further extends to nucleic acids encoding same and to methods of treating chronic inflammatory disease such... Agent: Nvip Pty Ltd
20140294816 - Combination therapy for the treatment of ocular neovascular disorders: The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention... Agent:
20140294807 - Combination therapy with type i and type ii anti-cd20 antibodies: The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a... Agent: Roche Glycart Ag
20140294812 - Fc variants that improve fcrn binding and/or increase antibody half-life: The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.... Agent: Xencor, Inc.
20140294814 - Humanized and affinity-matured anti-c-met antibody and uses thereof: Provided is a humanized and affinity-matured anti-c-Met antibody, a pharmaceutical composition including the antibody, and a method of preventing and/or treating c-Met-related disease using the antibody.... Agent: Samsung Electronics Co., Ltd.
20140294810 - Immunoglobulin variants and uses thereof: Variant immunoglobulins with one or more amino acid modifications in the Fc region that have increased in vivo half-lives, and methods of using the same are provided.... Agent: Genentech, Inc.
20140294811 - Method for predicting risk of hypertension associated with anti-angiogenesis therapy: The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determining the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the... Agent: Life Sciences Research Partners Vzw
20140294806 - Methods and compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate: This invention provides methods and compositions useful for treating early and late stage metastatic cancer to prevent or treat acquired resistance due to gene amplification or mutation in response to chemotherapeutic and/or targeted drugs. In particular, the methods and compositions include carboxiamidotriazole orotate (CTO) alone or in combination with specific... Agent:
20140294805 - Novel compounds and compositions for the inhibition of nampt: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below:... Agent:
20140294818 - Pgam1 inhibitors and methods related thereto: In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of... Agent: Emory University
20140294817 - Polypeptides comprising fc fragments of immunoglobulin g (igg) and methods of using the same: Polypeptides comprising at least a first and second Fc fragment of IgG that can be used to induce a stimulated cell to produce the anti-inflammatory cytokine Interleukin-10 and methods of using the same are disclosed herein.... Agent:
20140294813 - Tnf binding proteins: Provided are TNF binding proteins and methods of treatment using the same. Also provided are nucleic acids encoding the binding proteins and recombinant expression vectors and host cells for making such binding proteins.... Agent: Abbvie, Inc.
20140294808 - Treating cancer with hsp90 inhibitory compounds: Methods of treating cancer with a compound of formulae (I) or (Ia) are disclosed. Also provided are methods of treating a cancer with a mutation in ALK or a c-MET mutation with a compound of formulae (I) or (Ia). Further provided are methods of treating non-small cell lung cancer with... Agent: Synta Pharmaceuticals Corp.
20140294824 - Antibodies that bind to ox40 and their uses: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a... Agent: Glenmark Pharmaceuticals S.a.
20140294821 - Factor viii chimeric and hybrid polypeptides, and methods of use thereof: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing... Agent: Biogen Idec Hemophilia Inc.
20140294820 - Fibroblast growth factor receptor inhibition for the treatment of disease: Methods of inhibiting fibroblast growth factor mediated activation of fibroblast growth factor receptors for the treatment of chronic kidney disease, diabetes, and cardiac diseases are enclosed. Pharmaceutical compositions for the treatment of such diseases using the methods are also disclosed as are methods of determining whether a subject would benefit... Agent: University Of Miami
20140294823 - Heterodimeric proteins: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as... Agent: Xencor, Inc.
20140294825 - Hybrid constant regions: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and Cμ3 and Cμ4 regions of a Cμ constant region. The hybrids retain properties of both component constant... Agent: Jn Biosciences LLC
20140294822 - Methods and compositions for increasing arylsulfatase a activity in the cns: Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A.... Agent: Armagen Technologies, Inc.
20140294826 - Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure: Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes at least one or... Agent: Tufts University
20140294828 - Alphabodies specifically binding to viral proteins and methods for producing the same: The invention provides methods for the production of single-chain Alphabody polypeptides having detectable binding affinity for, or detectable in vitro activity on, a viral protein of interest, which comprising the step of producing a single-chain Alphabody library comprising at least 100 different-sequence single-chain Alphabody polypeptides, wherein said Alphabody polypeptides differ... Agent: Complix Sa
20140294829 - Anti-ngf antibodies for the treatment of various disorders: The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including pain, asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a significant adverse effect on the immune system of the patient.... Agent: Genentech, Inc.
20140294827 - Fully human antibodies that bind to vegfr2: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such... Agent:
20140294830 - Method of combination therapy using an egfr antagonist and anti-c-met antibody: A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.... Agent: Samsung Electronics Co., Ltd.
20140294831 - Methods of treating a tauopathy: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.... Agent: Ipierian, Inc.
20140294838 - Bispecific anti-cmet/anti-her2 antibodies: There are provided an anti-c-Met/anti-Her2 bispecific antibody, and a method for preventing and/or treating cancer using the same.... Agent: Samsung Electronics Co., Ltd.
20140294837 - Fusion protein comprising anti-c-met antibody and vegf-binding fragment: There are provided a fusion protein formed by coupling of anti-c-Met antibody and VEGF-binding fragment, a bispecific antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, a pharmaceutical composition comprising the bispecific antibody as an active ingredient, and a method for preparing the... Agent: Samsung Electronics Co., Ltd.
20140294839 - Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease: In sporadic Alzheimer's disease, neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. Immunoassays have been developed recently that detect tau in biological specimens, thus providing a means for pre-mortem diagnosis of Alzheimer's disease, which has remained elusive. These assays have been improved by... Agent:
20140294832 - Monoclonal antibodies against tissue factor pathway inhibitor (tfpi): Isolated monoclonal antibodies that bind to specific epitopes of human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided.... Agent: Bayer Healthcare LLC
20140294833 - Novel heterodimeric proteins: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light... Agent:
20140294835 - Novel heterodimeric proteins: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light... Agent: Xencor, Inc.
20140294834 - Tandem fc bispecific antibodies: Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region... Agent: Merrimack Pharmaceuticals, Inc.
20140294836 - Targeting regulatory t cells with heterodimeric proteins: The present invention provides methods and compositions comprising a heterodimeric antibody comprising a first monomer comprising a first variant heavy chain constant region and an anti-CD4 binding moiety. The heterodimeric antibody also comprises a second monomer comprising: a second variant heavy chain constant region and an anti-CD25 binding moiety. In... Agent: Xencor, Inc.
20140294840 - Expression of mirnas in placental tissue: Provided are human miRNAs associated with the generation of immunological tolerance during pregnancy as well as fragments, derivatives and variants thereof for use in immunomodulation. Said miRNAs may be used in diagnosis and treatment of disorders associated with a deregulated immune response, autoimmune disorders, pregnancy associated diseases, failure or problems... Agent:
20140294841 - T cell receptor-like antibodies specific for a wti peptide presented by hla-a2: The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion... Agent: Memorial Sloan-kettering Cancer Center
20140294845 - Anti-pleiotrophin antibodies and methods of use thereof: The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an... Agent: Georgetown University
20140294842 - Assays, methods and means: A novel class of hydroxylases is described having the amino acid sequence of SEQ ID No. 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF... Agent: Isis Innovation Limited
20140294847 - Biological materials related to c-met: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to... Agent: Ablynx N.v.
20140294849 - Compositions and uses: The invention provides a TLR agonist and an antibody which binds to an antigen such as a β-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before... Agent: Glaxosmithkline Biologicals Sa
20140294843 - Diagnosis and treatment of copd: Provided is a method for diagnosing and/or staging COPD based on detection of one or more histone proteins. In some embodiments, the histone protein is an H3.3 protein comprising a post-translational modification. In some embodiments, the histone protein is H2B, H3, H3.3 or H4. Kits for practicing the methods of... Agent: Temple University Of The Commonwealth System Of Higher Education
20140294846 - Function and regulation of adamts-1: The present invention relates to ADAMTS-1 and uses thereof. The present invention also relates to fragments of ADAMTS-1 and methods of inhibiting cell growth and metastasis. The present invention also provide methods of identifying inhibitors and activators relating to the function of ADAMTS-1.... Agent: The Trustees Of The University Of Pennsylvania
20140294848 - Novel targets for regulation of angiogenesis: The present invention relates to the identification of polynucleotides and polypeptides having increased expression in tumor blood vessels. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of angiogenesis and the diagnosis and treatment of angiogenesis-related... Agent: The University Of North Carolina At Chapel Hill
20140294844 - Prion protein antibodies for the treatment of alzheimer's disease: The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues... Agent: D-gen Limited
20140294850 - Early childhood membranous nephropathy due to cationic bovine serum albumin: The invention concerns a biomarker for diagnosing or prognosing childhood Membranous Nephropathy (MN), said biomarker is (i) cationic Bovine Serum Albumin (BSA), and/or (ii) an antibody that binds to a polypeptide of sequence SEQ ID NO: 3. The invention further concerns an antibody or antibody fragment or a composition comprising... Agent: Institut National De La Sante Et De La Recherche Medicate (inserm)
20140294851 - Cleavable drug conjugates, compositions thereof and methods of use: Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.... Agent:
20140294852 - Monoclonal antibodies to programmed death 1 (pd-1): The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions... Agent: Medarex, L.L.C.
20140294853 - Antagonistic dr3 ligands: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.... Agent: Novo Nordisk A/s
20140294854 - Target directed to adipocytes, methods and assays for treatment of obesity: The present invention provides compositions and methods for treating obesity in a subject by administering an inhibitor of UBE2L6 or an activator of adipocyte triglyceride lipase to the subject.... Agent: Albert Einstein College Of Medicine Of Yeshiva University
20140294856 - Combination treatment comprising a hdac6 inhibitor and an akt inhibitor: The invention provides compositions comprising a Histone Deacetylase 6 (HDAC6) inhibitor and an AKT inhibitor, pharmaceutical compositions/formulations and kits of parts comprising the same; optionally further comprising one or more anti-cancer agents. The compositions of the invention provide for surprisingly efficacious killing of inter alia, cancer cells. Thus, the invention... Agent:
20140294857 - Methods of obtaining a specific binding member that binds eotaxin: Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining... Agent: Medimmune Limited
20140294855 - Small molecule screening for mouse satellite cell proliferation: The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided is a method for repairing or regenerating a damaged muscle tissue of a subject.... Agent: President And Fellows Of Harvard College
20140294858 - Subcutaneous administration of anti-hepatitis b antibodies: The present application relates to an immunoglobulin preparation comprising anti-hepatitis B antibodies for subcutaneous administration and to uses thereof, including methods for treating, preventing and/or reducing a disease, disorder or condition associated with hepatitis B virus... Agent:
20140294859 - Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.... Agent: Amgen Inc.
20140294860 - Means and methods for treating and/or preventing natural ahr ligand-dependent cancer: The present invention relates to the field of cancer therapeutics and treatment of cancer. In particular, it relates to a method for treating and/or preventing a natural AHR ligand-dependent cancer comprising administering to a subject suffering from said cancer a therapeutically effective amount of an AHR inhibitor. Moreover, contemplated is... Agent: Deutsches Krebsforschungszentrum
20140294861 - Isolated b7-h4 specific compositions and methods of use thereof: The present invention relates to B7-H4-specific compositions and methods of use thereof.... Agent: The Trustees Of The University Of Pennsylvania
20140294862 - Methods of modulating the negative chemotaxis of immune cells: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.... Agent: Celtaxsys, Inc.
20140294864 - Drug conjugate composition: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that... Agent:
20140294863 - Serum albumin binding peptides for tumor targeting: Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion.... Agent: Genentech, Inc.
20140294865 - Amatoxin-conjugates with improved linkages: The invention relates to tumor therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.... Agent: Heidelberg Pharma Gmbh
20140294866 - Uses of myostatin antagonists: The present invention provides methods for treating disorders arising from hypogonadism by administering myostatin antagonists to subjects suffering from such disorders.... Agent:
20140294868 - Pyrrolobenzodiazepines and conjugates thereof: e
20140294867 - Site-specific antibody-drug conjugation through glycoengineering: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells... Agent: Genzyme Corporation
20140294871 - Amino acid sequences for controlling pathogens: The present invention relates to antimicrobial peptides, isolated and purified from extracts of tilapia (Oreochromis niloticus) gills. Such peptides may be produced by chemical synthesis or by expression in heterologous systems, such as bacteria and yeasts, by conventional molecular biology techniques. These peptides show antimicrobial activity against various organisms, including... Agent: Centro De Ingenieria Genetica Y Biotecnologia
20140294874 - Apoaequorin for reducing neuronal injury due to ischemia: The present invention provides apoaequorin-based compositions and methods for preconditioning neurons in a subject to reduce neuronal injury due to brain ischemia. Methods include the step of administering apoaequorin to neurons in a subject, wherein the apoaequorin initiates a change in cytokine expression levels resulting in a reduction of neuronal... Agent:
20140294870 - Autoimmune and inflammatory disorder therapy: Compounds that bind to phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) and inhibit the binding of PI4KIIIβ to its substrate and/or inhibit PI4KIIIβ activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating... Agent: Katholieke Universiteit Leuven, K.u.leuven R&d
20140294869 - Immune tolerance inducer: An object of the present invention is to provide a drug and a method for effectively inducing donor-specific immune tolerance in a recipient in transplantation therapy. A complex of an siRNA for a costimulatory factor and schizophyllan is delivered to a Dectin-1 expressing cell which specifically recognizes schizophyllan to regulate... Agent: Napajen Pharma, Inc.
20140294872 - Methods of preparing lyophilized spherical-shaped pellets of biological materials: Methods for preparing lyophilized pellets of biological materials are described. The pellets have a substantially spherical shape and are prepared by freezing droplets of a liquid composition of a desired biological material on a flat, solid surface, in particular, a surface that does not have any cavities, followed by lyophilizing... Agent:
20140294873 - Small molecule screen for inhibitors of nfat: ap-1: dna interactions: The invention provides a screening assay for selecting inhibitors of NFAT:Transcription factor interactions. The invention also provides compositions and methods for inhibiting immune response in a subject.... Agent: Children Medical Center Corporation
20140294876 - Amyloid beta 1-6 antigen arrays: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an Aβ1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least... Agent: Novartis Ag
20140294877 - Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids: The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule,... Agent: Curevac Gmbh
20140294878 - Hypoallergenic variants of mal d 1, the major allergen from malus domestica: Disclosed are hypoallergenic variants of Mal d 1, the major allergen from Malus domestica, and the uses thereof in the treatment of allergic diseases.... Agent: Lofarma S.p.a
20140294875 - Leishmania vaccine using sand fly salivary immunogen: The present invention provides vectors that contain and express in vivo or in vitro sand fly Lu. longipalpis salivary antigens that elicit an immune response in animal or human against Leishmania, vaccine compositions comprising said vectors and/or Lu. longipalpis salivary polypeptides, methods of vaccination against Leishmania, and kits for use... Agent: Merial Limited
20140294879 - Modified rsv f proteins and methods of their use: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.... Agent: Novavax, Inc.
20140294880 - Mutated lentiviral env proteins and their use as drugs: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.... Agent: Centre National De La Recherche Scientifique
20140294887 - Adjuvanting meningococcal factor h binding protein: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge... Agent:
20140294882 - Compositions and methods for detecting, treating, and protecting against fusobacterium infection: The present invention relates to protecting against, treating, and detecting Fusobacteria infections. Compositions and methods derived from nucleic acid and protein sequences of a 40 kDa Adhesin protein are provided to protect against, treat, and detect Fusobacteria infections in a subject. In one aspect, vaccines capable of inducing an immune... Agent: Kansas State University Research Foundation
20140294885 - Heterologous expression of neisserial proteins: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.... Agent: Novartis Ag
20140294886 - Isolated protein and compositions comprising the protein: Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[-X-L-]n-B-COOH where X is an amino acid sequence, L is an optional linker amino acid sequence. A is an optional N-terminal amino acid sequence, B is... Agent:
20140294884 - Meningococcus adhesins nada, app and orf 40: NadA, App and ORF40 function as adhesins in N. meningitidis. Adhesion nad be modulated by targeting these three proteins. NadA allelic variants are also disclosed. Autoproteolytic cleavage of App is disclosed, as is removal of the activity by mutagenesis. App is processed and secreted into culture medium when expressed in... Agent: Novartis Vaccines And Diagnostics Srl
20140294881 - Proteases producing an altered immunological response and methods of making and using the same: The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention... Agent: Danisco US Inc.
20140294888 - Protective vaccine based on staphylococcus aureus sa2451 protein: The present invention relates to methods of inducing an immune response to Staphylococcus comprising administering a composition comprising an SA2451-related polypeptide from Staphylococcus aureus as well as derivatives or fragments thereof. The present invention also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a... Agent:
20140294883 - Vaccine: The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately 50 kDa of A. hydrophila for use in the development of a vaccine, as well as the nucleic acid encoding said protein... Agent: University Of Stirling
20140294889 - Use of the pacap as a molecular adjuvant for vaccines: The present invention relates to the use of the pituitary adenylate cyclase activating peptide (PACAP) as a molecular adjuvant for vaccines. Among other applications, these vaccines may be used in the protection against infectious agents such as viruses, bacteria and ectoparasites affecting mammals, birds and aquatic organisms. The PACAP, combined... Agent: Centro De Ingenieria Genetica Y Biotecnologia
20140294892 - Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.... Agent:
20140294891 - Microorganisms for therapy: Therapeutic methods and vaccinia virus therefor are provided. The viruses are designed so that they accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms.... Agent:
20140294890 - Recombinant adenovirus vaccines: Recombinant adenovirus vaccines comprising recombinant adenoviruses whose hexon, fiber or protein IX capsid proteins are engineered to include exogenous peptide segments, e.g. vaccines for human papillomavirus (HPV) and malaria.... Agent: The Johns Hopkins University
20140294893 - Recombinant nonpathogenic mdv vector providing multivalent immunity: The present invention relates to the field of veterinary vaccines, in particular to that of vector vaccines for poultry based on recombinant nonpathogenic Marek's disease virus (npMDV). The recombinant npMDV of the invention expresses stably and effectively two heterologous genes each originating from a different micro-organism: the fusion protein gene... Agent:
20140294894 - Transcutaneous delivery of therapeutic agents: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction... Agent: Alba Therapeutics Corporation
20140294895 - Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines: Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark,... Agent: University Of Central Florida Research Foundation, Inc.
20140294896 - Cancer antigen: Cancer cells when treated with cisplatin, paclitaxel, gemcitabine, Mycobacterium w or combination there of shows altered protein profile. Thus altered protein profile has at least one protein commonly expressed or over expressed. The commonly expressed or over expressed protein induces immune response specific to cancer cells (homologue and hetrologus) of... Agent:
20140294898 - Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.... Agent:
20140294897 - Potent lna oligonucleotides for the inhibition of hif-1a expression: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-(Tx)GxGxcsasasgscsastscscsTxGxT-3′ and 5′-(Gx)TxTxascstsgscscststscsTxTxA-3′, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link... Agent: Santaris Pharma A/s
20140294899 - Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate: A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker... Agent: Teva Pharmaceutical Industries Ltd.
20140294900 - Flagellin related polypeptides and uses thereof: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptsis is described.... Agent: Cleveland Clinic Foundation
20140294903 - Methods and compositions for treating hiv-associated diarrhea: Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In... Agent:
20140294902 - Novel a4b7 peptide antagonists: The invention relates to disulfide-rich peptide molecules which inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against α4β1 binding.... Agent: Protagonist Therapeutics, Inc.
20140294901 - Novel a4b7 peptide dimer antagonists: The invention relates to disulfide-rich dimer molecules which inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against α4β1 binding.... Agent: Protagonist Therapeutics, Inc.
20140294904 - Water-in-oil emulsions and methods for their preparation: The present invention relates to a water-in-oil emulsion, comprising a continuous hydrophobic phase in which the hydrophilic phase is dispersed, wherein: (i) the emulsion has a total water content in the range of 30% to 95% (w/w); (ii) the emulsion does not comprise an emulsion stabilizer; (iii) the hydrophobic phase... Agent:
20140294905 - Antimicrobial textiles: This invention is about textiles which are equipped with antifungal, anticandidal and antibacterial properties. The aim of the invention is to attain antimicrobial textiles which reduces the incidence of infections communicated or spread by textiles, reduces the loss of extra cost and energy to ensure hygiene and strengthens the hygienic... Agent:
20140294906 - Method for conferring antimicrobial activity to a substrate: In one embodiment, the invention relates to a method for rendering a non-metallic substrate stably antimicrobial. The method comprises: (a) contacting the substrate with an antimicrobial surfactant; (b) contacting the substrate with a polymeric binder; and (c) subjecting the substrate, surfactant, and binder to conditions at which the substrate becomes... Agent: Research Foundation Of The City University Of New York
20140294907 - Antagonistic properties of reef fish microflora: Disclosed herein are methods for preventing biofilm formation on a surface. The present disclosure also relates to anti-biofilm forming agents, to methods of producing and using them, and to anti-fouling coatings produced therefrom.... Agent:
20140294909 - Nanocomposites of gold and polymers: A layer-by-layer (LbL) system, which alternately ionically complexes anionic AuNPs to two unique cationic polymers (disulfide-reducible and hydrolytically degradable) and two anionic nucleic acids, is disclosed.... Agent: The Johns Hopkins University
20140294908 - Supporting material for cell sheet: Provided in one embodiment is an implantable support material for culturing cells, wherein at least some of the cells substantially maintain at least one of (i) phenotype and (ii) genotype thereof after being cultured on the support material.... Agent:
20140294912 - Amorphous poly(d,l-lactide) coating: Implantable devices formed of or coated with a material that includes an amorphous poly(D,L-lactide) formed of a starting material such as meso-D,L-lactide are provided. The implantable device can be used for the treatment, mitigation, prevention, or inhibition of a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation,... Agent:
20140294911 - Cartilage material: Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or... Agent: Vivex Biomedical Inc.
20140294910 - Implantable materials having engineered surfaces and method of making same: An implantable biocompatible material includes one or more vacuum deposited layers of biocompatible materials deposited upon a biocompatible base material. At least a top most vacuum deposited layer includes a homogeneous molecular pattern of distribution along the surface thereof and comprises a patterned array of geometric physiologically functional features.... Agent: Palmaz Scientific, Inc.
20140294913 - Biodegradable bone fillers, membranes and scaffolds containing composite particles: This invention is related to bone fillers, hard tissue supporting films and three dimensional scaffolds that contains composite particle of inorganic compound/water soluble polymer (such as β-TCP/Gelatin), that can lead to bone regeneration and release an antibacterial or bioactive agent at the defect area. The bone regenerative hard tissue supporting... Agent:
20140294914 - Intraocular encapsulation of oxygenic bacteria: Exemplary embodiments comprise an implantable ophthalmic device comprising at least one shell encapsulating oxygenic bacteria and growth medium and designed to increase the oxygen partial pressure in an oxygen-deprived structure of or space within, an eye. Exemplary embodiments may be used therapeutically to treat ischemic retinopathies in situ and thereby... Agent: The Regents Of The University Of Colorado, A Body Corporate
20140294915 - Chewing gum with tomatidine: A chewing gum with a liquid-fill composition and a surrounding gum region, with one or both containing active ingredients, such as herbal, medicinal and/or mineral elements or combinations thereof, present in an amount of at least about 0.05 mg.... Agent:
20140294916 - Methylphenidate extended release chewable tablet: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose... Agent:
20140294917 - Thermoset and thermoplastic fibers and preparation thereof by uv curing: In one embodiment, this invention is directed to a method of preparing a thermoset or thermoplastic polymer fiber comprising the following sequential steps: (i) providing a monomeric or oligomeric mixture, wherein said monomeric or oligomeric mixture comprises monomers or oligomers which polymerize by radiation; (ii) optionally heating or cooling said... Agent:
20140294918 - Matricryptic ecm peptides for tissue reconstruction: Chemoattractant polypeptide compounds for progenitor cells and compositions and drug products comprising the compounds are provided herein. Methods for attracting progenitor cells to a location in or on a patient also are provided along with methods of growing and repairing bone.... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education
20140294919 - Vaccines: The present invention relates to efficient devices for administration of pharmaceutical agents into the skin of the human body. In particular the present invention provides devices for vaccination into the skin. The present invention provides a pharmaceutical agent delivery device having skin-piercing portion comprising a solid reservoir medium containing the... Agent:
20140294920 - Transdermal propranolol patch for treatment of malignant melanoma: A transdermal d propranolol or racemic propranolol patch for use as an adjunct to surgery in the treatment of malignant melanoma and/or tattoo related applications are herein disclosed.... Agent:
20140294923 - Acth for treatment of migraine headache: Provided herein are methods of treatment of migraine headaches comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.... Agent: Questcor Pharmaceuticals, Inc.
20140294941 - Anti-angiogenic compositions and therapeutic applications thereof: There is described the use of the Human herpesvirus type 6 (HHV-6) U94 gene and its product, the protein Rep, expression vectors and pharmaceutical compositions suitable for the delivery of the U94 gene or the protein encoded therefrom to the therapeutic sites, to inhibit angiogenic and lymphangiogenic processes in a... Agent:
20140294942 - Antiviral peptides effective against hepatitis c virus: In certain embodiments this invention provides novel antiviral peptide(s) that are effective against positive sense RNA viruses that have an internal ribosome entry site (IRES). The peptide(s) can be used to inhibit propagation of such viruses and thereby provide a effective modality for the treatment of infections such as hepatitis... Agent: The Regents Of The University Of California
20140294934 - Cationic lipids for therapeutic agent delivery formulations: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; wherein X is selected from a... Agent: Nitto Denko Corporation
20140294933 - Composition for delivery of angiogenesis inducing molecule and artificial tissue prepared by the composition: A composition for delivery of an angiogenesis inducing agent, including a temperature-sensitive liposome, a vascular cell-specific antibody, and an angiogenesis inducing agent, a tissue culture obtained using the composition, an artificial tissue including the tissue culture, and a method for preparing an artificial tissue are provided.... Agent: Samsung Electronics Co., Ltd.
20140294921 - Composition for tipical use for treating skin disorders: It is described a composition, topically administrable, comprising as active ingredients L-carnitine or a derivative thereof, biotin, and at least one or more of the following active ingredients: vitamin B 12; vitamin E; bisabolol; and panthenol; useful for treating skin disorders.... Agent: Sigma-tau Industrie Famaceutiche Riunite S.p.a.
20140294936 - Compositions and methods for inhibiting expression of the hamp gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part... Agent:
20140294929 - Compositions for delivery of cargo such as drugs proteins and/or genetic materials: Compositions and methods for delivery of cargo molecules to a patient or subject in need thereof include a proteoliposome carrier vehicle that incorporates an RLIP76 protein and contains the cargo molecule. The vehicle effectively delivers the cargo molecule systemically throughout the tissues of the body including into the central nervous... Agent: Terapio Corporation
20140294928 - Compositions of polymeric myrcene: The invention relates to compositions and formulations comprising polymeric myrcene. More particularly, the invention relates to compositions comprising an isolated fraction of polymeric myrcene in a hydrophobic carrier and formulations which maintain the biological activity of the active polymer.... Agent: Regenera Pharma Ltd.
20140294922 - Compound with antibacterial activity: It is described the use of betamethasone as antibacterial agent.... Agent: Sigma-tau Industrie Farmaceutiche Riunite S.p.a.
20140294925 - Formulations combining ramoplanin and rhamnolipids for combating bacterial infection: Provided herein are methods of treating a superbug infection in a subject that include administering to the subject a therapeutically effective dose of ramoplanin in combination with a therapeutically effective dose of one or more rhamnolipids, thereby treating the superbug infection. The superbug may be vancomycin-resistant Enterococcus, Clostridium difficile, or... Agent: Agae Technologies LLC
20140294937 - Lipid compositions for nucleic acid delivery: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic... Agent:
20140294931 - Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders: Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes,... Agent: Nanopharmaceuticals LLC
20140294943 - Methods of using microrna 195 in providing neuroprotection: The invention relates to a method for providing neuroprotection comprising administering to a subject an effective amount of a miRNA or a variant thereof. By providing neuroprotection, or ischemic stroke can be prevented and/or treated.... Agent: Kaohsiung Medical University
20140294938 - Mrna therapy for fabry disease: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.... Agent:
20140294940 - Mrna therapy for urea cycle disorders: Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids. The compositions disclosed herein demonstrate a high transfection efficacy and are capable of ameliorating diseases associated with protein or enzyme deficiencies.... Agent:
20140294939 - Pulmonary delivery of mrna: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.... Agent:
20140294924 - Regeneration of pancreatic islets and reversal of diabetes by islet transcription factor genes delivered in vivo: The present invention includes compositions and methods for regenerating glucose-responsive cells by ultrasound-targeted microbubble destruction in the pancreas, wherein the composition comprises a pre-assembled liposome-nucleic acid complex in contact with within and about a microbubble, wherein the pre-assembled liposome-nucleic acid complex comprises a NeuroD gene under the control of the... Agent: Baylor Research Institute
20140294930 - Streptococcal glcnac-lacking glycopolypeptides, cell wall carbohydrates, streptococcus vaccines, and methods for making and using them: In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and... Agent: The Regents Of The University Of California
20140294927 - Synthetic nanostructures including nucleic acids and/or other entities: Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as... Agent: Northwestern University
20140294932 - Temperature sensitive liposome including cationic lipid and use thereof: Provided are a liposome including a cationic lipid, a pharmaceutical composition for the delivery of anionic drugs, and a method for delivering anionic drugs to a target site.... Agent: Samsung Electronics Co., Ltd.
20140294926 - Treatment for exposure to nerve agent: The present application provides methods of preventing and treating the toxic effects of exposure to organophosphate agents. In embodiments, targeted cationic liposome complexes delivering nucleic acid molecules encoding butyrylcholinesterase and a polyproline rich peptide are administered. Suitably, the administration is via inhalation or via aerosol. Also provided are cationic liposome... Agent: Georgetown University
20140294935 - Vaccine composition: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the... Agent:
20140294945 - Methods and devices for forming treatment agent carriers: A method is described including passing a solution having a biodegradable polymer, a solvent and a treatment agent through an electrocharged nozzle to form particles encapsulating the treatment agent. The particles emitted from the electrocharged nozzle may be exposed to a charge opposite that of the nozzle. The particles may... Agent:
20140294944 - Microencapsulation of oxygen liberating reactants: There is provided a composition for the delivery of oxygen having microencapsulated peroxide and microencapsulated catalyst that liberate oxygen upon sufficient contact with each. The components may be stored separately or together until use. Upon mixing, oxygen is liberated. The composition can be used for wound healing or for cosmetic... Agent: Kimberly-clark Worldwide, Inc.
20140294946 - Pharmaceutical compounds: wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof; have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer,... Agent:
20140294947 - Tamper resistant immediate release formulations: Disclosed in certain embodiments is an oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising a gelling agent; (ii) an optional barrier layer encompassing the core; (iii) an active layer comprising a drug susceptible to abuse encompassing the core or barrier layer; and (iv)... Agent:
20140294948 - Composition as auxiliary means for oral medication: The invention relates in one aspect to a composition, specifically a jelly, the use of which composition as an auxiliary means is to ease the taking of oral medication in solid form, which composition comprises iota-carrageenan as a jellifying agent and citric acid as a salivating agent, characterized in that... Agent: Paxtree Ltd
20140294949 - Vermin poison: Use of an orally or nasally available formulation of Tretazicar for poisoning vermin. An orally available or nasally available formulation of Tretazicar, wherein in the orally available formulation the Tretazicar is protected from acid hydrolysis, and provided that the formulation is not solid Tretazicar in a gelatin capsule. A formulation... Agent:
20140294950 - Methods of treating obesity in responder and non-responder populations: The disclosed embodiments relate to, dosing regimens for the administration of topiramate, optionally in combination with one or more sympathomimetic agents such as phentermine. The dosing regimens can, for example, limit the exposure of subjects to topiramate, identify subjects who are unlikely to obtain a benefit from treatment with escalating... Agent:
20140294951 - Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipide: The invention provides pharmaceutical compositions, methods for the treatment of and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the... Agent:
20140294953 - Abuse-resistant formulations: The disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 percent of the hydromorphone is released. In addition,... Agent:
20140294952 - Dissolvable medication admisistration bag and method of using the same: A dissolvable medication administration bag for the safe and effective crushing and administration of medication to patients who have difficulty swallowing pills is disclosed herein. In some embodiments, the dissolvable medication administration bag is constructed in accordance with a pill crusher pouch embodiment into which a pill is placed prior... Agent:
20140294954 - Misuse preventative, controlled release formulation: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a first layer and a second layer. The core comprises a superabsorbent material (for example, polycarbophil), and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core. When... Agent:
20140294955 - Misuse preventative, controlled release formulation: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a superabsorbent material. When crushed, either intentionally... Agent: Paladin Labs (barbados) Inc.
20140294956 - Gastric retentive extended release pharmaceutical compositions: The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition... Agent:
20140294957 - Niclosamide for the treatment of cancer metastasis: The invention relates to niclosamide and derivates thereof, which effectively inhibit transcription of the S100A4 gene, resulting in inhibition and/or reduction of S100A4-induced cell motility, invasiveness, metastasis and proliferation of human cancer cells.... Agent: Maxdelbruck-centrum Fur Molekulare Medizin
20140294958 - Lubricious coatings: The present invention relates to lubricious coatings comprising an ionomer and a hydrophilic polymer wherein the ionomer is cross-linked using a suitable cross-linking agent, and optionally also conventional excipients, such as a surfactant, a plasticizer and/or a filler. The invention also relates to pharmaceutical products covered by such lubricious coatings,... Agent:
20140294959 - Pharmaceutical composition of rosuvastatin calcium: The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.... Agent: Astrazeneca Uk Limited
20140294960 - Implantable modular hydrogel for salivary gland restoration: Implantable modular hydrogels to aid in salivary gland restoration and associated methods are provided. In one embodiment, the present disclosure provides for a hydrogel network comprising: a hyaluronic acid macromer crosslinked with a multiblock copolymer.... Agent:
20140294971 - Cancer cell-inhibiting ceramic, process for producing cancer cell-inhibiting ceramic, method for treating bone tumor, and use of beta-tricalcium phosphate porous granules with particle size of 1 to 10 micrometer: Proliferation of cancer cells is effectively inhibited. Provided is a cancer cell-inhibiting ceramic containing a β-tricalcium phosphate porous granule with a particle size of 1 to 10 μm. The β-tricalcium phosphate porous granule is taken up into cancer cells at an affected area and have an effect of inhibiting proliferation... Agent: National University Corporation Tokyo Medical And Dental University
20140294965 - Compositions and methods for exfoliating particles: Various embodiments provide compositions for exfoliating particles and methods for their manufacture. In one exemplary embodiment, the exfoliating particles may comprise a derivative of a botanically-sourced emollient, stearyl stearate, and at least one of: candelilla wax, is bran wax, sunflower wax, jojoba esters, carnauba wax, bees wax, corn wax, a... Agent:
20140294964 - Compositions and methods for treating cancer with dacarbazine nanoemulsions: A uniform microfluidized nanoemulsion is disclosed containing an anti-cancer agent, such as dacarbazine. The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of anticancer agents. As a nanoemulsion, dacarbazine has a greater anti-cancer efficacy than when... Agent:
20140294974 - Cosmetic composition: The invention relates to a cosmetic composition comprising an emulsion comprising hydrophobically modified particles, amino functionalized silicone and water; the cosmetic composition further comprising a moisturizing agent and at least one component selected from the group consisting of vitamin, anti-dandruff agent and surfactant, wherein the composition comprises at least a... Agent: Conopco, Inc. D/b/a Unilever
20140294976 - Cosmetic preparation comprising pulverized hydrophilic substances: A substance, which is in principle insoluble in a cosmetic or dermatological anhydrous preparation is converted into a powdery product by absorption onto a carrier, the powdery product being soluble in the preparation. The anhydrous preparations comprise one or more hydrophilic substances or substance mixtures which are liquid, pasty at... Agent:
20140294961 - Hepatic protection agent containing eggshell membrane and pharmaceutical composition, food additive and food using the same: The hepatoprotective agent contains eggshell membrane-containing fine powder, wherein the eggshell membrane-containing fine powder is eggshell membrane-containing fine powder having a volume mean particle diameter of 6 μm or less and/or eggshell membrane-containing fine powder having a volume maximum particle diameter of 20 μm or less. When fed with feed... Agent: The University Of Tokyo
20140294969 - Method and formulation for inhalation: This invention relates to drug delivery and in particular to the delivery of biologically active agents in the form of dry powders for inhalation. The invention also relates to methods for preparing such dry powder formulations and methods for their use.... Agent: Monash University
20140294962 - Method of preparing polymorphic pure form a of bazedoxifene acetate: The present invention provides a reliable process for the preparation of polymorphic pure form A of Bazedoxifene x acetate. In addition, the present invention relates to a process of wet granulation of polymorphic pure form A of Bazedoxifene x acetate. The present invention also relates to pharmaceutical compositions comprising polymorphic... Agent: Sandoz Ag
20140294963 - Novel gold-platinum based bi-metallic nanocrystal suspensions, electrochemical manufacturing processes therefor and uses for the same: The present invention relates to novel gold-platinum based bi-metallic nanocrystal suspensions that have nanocrystal surfaces that are substantially free from organic or other impurities or films associated with typical chemical reductants/stabilizers and/or raw materials used in nanoparticle formation processes. Specifically, the surfaces are “clean” relative to the surfaces of metal-based... Agent:
20140294972 - Oral suspension: A liquid pharmaceutical composition for use in the treatment of acute lymphoblastic leukaemia (ALL) comprising 6-mercaptopurine or a salt, hydrate or solvate thereof and a pharmaceutically-acceptable excipient, wherein the composition is a suspension for oral administration, a kit of parts for the accurate dosing and administration of the liquid pharmaceutical... Agent: Nova Bio-pharma Technologies Limited
20140294973 - Pharmaceutical compositions of hydrophobic camptothecin derivatives: The present invention provides a pharmaceutical composition comprising at least one hydrophobic camptothecin derivative or a pharmaceutically acceptable salt of said derivative and a polyethylene glycol (PEG) conjugated phospholipid. Also provided is a method to inhibit cancer cells in a subject in need thereof by administering the pharmaceutical composition of... Agent:
20140294968 - Polyacrylate-based active compound-comprising particles: The invention relates to novel polyacrylate-based active compound-comprising particles which bind to hair, and to the use of these particles for preparing medicaments, in particular for veterinary medicine. The particles comprise uncharged and cationic polyacrylate and are at most 10 um big.... Agent: Bayer Intellectual Property Gmbh
20140294977 - Radiation-sterilized biodegradable drug delivery composition: The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing... Agent: Durect Corporation
20140294975 - Solid anti-sun composition based on lipophilic organic uv screening agent and aerogel particles of hydrophobic silica: The present invention thus relates to a solid composition, in particular in the form of a loose or compact powder, comprising, in a cosmetically acceptable medium: a) at least one pulverulent phase; b) at least one lipophilic organic UV screening agent characterized in that the pulverulent phase comprises at least... Agent:
20140294970 - Stabilized pharmaceutical sub-micron suspensions and methods of forming same: The present invention is directed to a pharmaceutical submicron suspension and a method of forming the submicron suspension. The submicron suspension is useful for delivery of relatively hydrophobic and/or low solubility therapeutic agent. The submicron suspension and method of forming the submicron suspension typically employ a polymeric material that aids... Agent:
20140294966 - Stable nanocomposition comprising docetaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it: A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked... Agent: Bbs Nanotechnology LLC.
20140294967 - Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it: A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked... Agent: Bbs Nanotechnology LLC.
20140294981 - Carbon encapsulated transition metal oxide nanocomposite, a method for its preparation and its use in li-ion batteries: A nanocomposite includes carbon-encapsulated transition metal oxide nanoparticles. The carbon-encapsulated transition metal oxide nanoparticles comprise a transition metal oxide core having a diameter of from 5 nm to 50 nm covered by a graphitic coating having a thickness of from 1 nm to 5 nm.... Agent:
20140294978 - Cationic lipid: n
20140294979 - Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression: Methods and pharmaceutical compositions for regulations of Guanosine- (G-) and/or Guanosine-cytosine-rich (GC-rich) nucleic acid expressions are provided. The methods include a step of interacting the G- and/or GC-rich region of the nucleic acid with thalidomide, and the pharmaceutical compositions include the thalidomide and a pharmaceutical carrier.... Agent: National Yang-ming University
20140294980 - Sustained release particle formulations: Particles for delivery of active ingredients formed from an active ingredient and a hydrophobic matrix, as well as methods for making such particles.... Agent:
20140294982 - Nanoparticle compositions for generation of regulatory t cells and treatment of autoimmune diseases and other chronic inflammatory conditions: The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the... Agent:
20140294983 - Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it: A nanoparticulate composition for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either... Agent: Bbs Nanotechnology Ltd.
20140294984 - Compacted rumen protected nutrient pellets and method of manufacture: A process for producing a compacted rumen-protected nutrient pellet and the resultant pellet. The process includes the steps of (i) blending a C4-24 fatty acid and a biologically active ingredient to form solid central core particles, (ii) compacting the core particles to form pellets, and (iii) sequentially coating the pellets... Agent: Quali Tech, Inc.
20140294985 - Bone pastes comprising biofunctionalized calcium phosphate cements with enhanced cell functions for bone repair: The invention provides injectable, biofunctional agent-containing calcium phosphate cement bone pastes for bone tissue engineering, and methods of making and using the same.... Agent: University Of Maryland,baltimore
20140294986 - Microsphere drug delivery system for sustained intraocular release: Disclosed are biodegradable microspheres between 40 μm and 200 μm in diameter that are effectively retained in the anterior chamber of the eye without producing hyperemia. The microspheres generally contain a drug effective for the treatment of an ocular condition and include a biodegradable polymer matrix that can provide for... Agent: Allergan, Inc.
20140294987 - Plant derived seed extract rich in essential fatty acids derived from perilla seed: composition of matter, manufacturing process and use: A composition of matter comprises a shelf stable, super critical, CO2 fluid extracted seed oil derived from a cracked biomass of perilla frutescens, the seed oil comprising from about 60 to about 95 percent w/w of PUFAs in a ratio of from about 4:1 to about 6:1 alpha-linolenic acid (ALA)... Agent:
20140294988 - Skin treatment formula for psoriasis: A topical treatment is disclosed for combating psoriasis comprising a combination of coconut oil, cocoa butter, olive oil, beeswax and rose oil. Versions of the formula also may contain neem oil, jojoba oil and/or salicylic acid. The formula is topically applied to the skin after a washing and can be... Agent:
20140294989 - Copper-and-titanium-containing composition and production method therefor: The Cu- and Ti-containing composition of the present invention contains titanium oxide including rutile-crystal-type titanium oxide, and a divalent copper compound, wherein the rutile-crystal-type titanium oxide exhibits the most intense diffraction peak attributed to rutile-type titanium oxide having a full width at half maximum of 0.65° or less, in a... Agent: Showa Denko K.k.
20140294991 - Medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent: The present invention provides a combination of rebamipide and a tear-retaining agent as a medicament for the treatment of anterior eye diseases.... Agent:
20140294990 - Throat gargle tablet and method of use thereof: An anhydrous composition is provided. The anhydrous composition may be a tablet configured to dissolve in water, the tablet including Vitamin C (as ascorbic acid), Vitamin E (as dl-alpha-tocopheryl acetate), Magnesium (as magnesium sulfate and magnesium oxide), Zinc (as zinc sulfate), Chloride (as sodium chloride), Sodium (as sodium chloride, sodium... Agent:
20140294992 - Highly stable electrolytic water with reduced nmr half line width: Electrolytic acid or alkaline water having a NMR half line width using 17O of from about 45 to less than 51 Hz, and an oxide reduction potential of from −1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to... Agent: Apr Nanotechnologies S.a.
20140294993 - Method for treatment of mesothelioma: The present invention provides that Ras-like, estrogen-regulated, growth inhibitor (RERG) is a malignant mesothelioma biomarker of clinical course and treatment sensitivity and, itself a target for mesothelioma treatment. A low RERG level in a mesothelioma subject indicates poor prognosis. Analyzing RERG expression level along can help mesothelioma patients make treatment... Agent: The Brigham And Women's Hospital, Inc.
20140294994 - Pharmaceutical composition for elimination of cancer stem cells: The preset invention relates to use of antipsychotic phenothiazine derivative for eliminating cancer stem cells (CSCs) and/or preventing a cancer. The invention also provides a pharmaceutical composition for treating a cancer, and/or preventing or delaying cancer recurrence comprising trifluoperazine and an anti-cancer drug, such as gefitinib or cisplatin.... Agent:
20140294995 - Lozenge for treating sore throat, hoarseness and associated dry cough, and inflammatory diseases of the oral and pharyngeal cavity: The present invention relates to a pharmaceutical formulation containing a combination of (a) at least one astringent active substance and (b) at least one mucilaginous drug and the use thereof for the prevention or treatment of inflammatory diseases of the oropharyngeal region and for the treatment of painful irritations of... Agent: Boehringer Ingelheim International Gmbh
20140294996 - One or more of vigna marina, cocos nucifera l. or terminalia catappa l. extracts for treating wounds, skin disorders and hair loss: Biologically active extracts of one or more Vigna marina (Burm.) Merr., Cocos nucifera L., or Terminalia catappa L, and compositions one or more of the extracts are described. The invention also provides therapeutic and cosmetic uses of the extracts and compositions, in particular for promoting wound healing and for the... Agent:
20140294997 - Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodites to microbiota of firmuctes phylum: A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit... Agent: Nume Health Inc.
20140294998 - Novel herbal composition: Disclosed herein is synergistic herbal composition comprising extracts of herbal ingredients of Tribulus terrestris, Withania somnifera, Curculigo orchioides, Mucuna pruriens, Asparagus adscendens, Asteracantha longifolia, Asphaltum, and optionally the extracts of Piper longum and Anagclus pyrethrum for the treatment of disorders associated with Male Sexual Dysfunction.... Agent:
20140294999 - Natural weight reduction health composition and application thereof: Health-care composition made from the combination of herbal materials and a compound with a known effect of losing weight. The herbal materials are Balsam pear and dried tangerine peel and the known for losing weight is L-carnitine L-tartrate. Such combination not only achieves a comprehensive benefficiary effect on obesity but... Agent: Infinitus (china) Company Ltd.
20140295000 - Herbal extract products and methods: The present invention relates to a product for topical administration in particular, a product for use in the treatment of eczema and psoriasis and other related conditions.... Agent:
20140295001 - Herbal/organic composition for the management of pain: An herbal/organic composition for the treatment and management of pain contains about 0.01 wgt % Boswellia extract, about 0.01 wgt % ginger extract, about 0.01 wgt % holy basil extract, about 0.01 wgt % rosemary extract, about 0.01 wgt % turmeric extract, about 0.01 wgt % white willow extract, about... Agent:
20140295003 - Methods for improving health in canines: A method of improving health in a canine includes administering to the canine a nutritional supplement comprising an amino acid secretagogue composition, which stimulates the pituitary gland of the canines to produce growth hormone. The nutritional supplement may be administered orally. The nutritional supplement may comprise L-arginine hydrochloride, Oxo-proline, L-lysine... Agent:
20140295002 - Methods for improving health in humans: Embodiments of the invention generally relate to methods and supplements for improving the health of human beings.... Agent:
20140295004 - Bioactive botanical cosmetic compositions and processes for their production: The present invention is directed to bioactive botanical cosmetic compositions derived from membrane and cell serum fractions of plant cell juice. The present invention also relates to the methods for preparing these bioactive botanical cosmetic compositions and the uses of these compositions in various cosmetic formulations and as topical skin... Agent: Akzo Nobel Surface Chemistry LLC
20140295005 - Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof: Disclosure provides a formulation of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin and to augment the biological activity of curcumin, wherein curcumin is the main constituent of curcuminoid and wherein Ar-turmerone is the main constituent of the essential oil of turmeric. An application of curcuminoid... Agent:
20140295006 - Herbal composition for treating metastatic breast cancer: The invention provides a composition comprising a mixture of extracts obtained from Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla, and Viola philippica. The present invention further provides a method for treating metastatic breast cancer in a subject... Agent:
20140295007 - Topical skin treatment composition comprising dendranthema indicum extract: The present invention relates to a topical skin treatment composition comprising Dendranthema indicum extract and, more particularly, to a topical skin treatment composition containing Dendranthema indicum extract which is excellent for the anti-oxidation, anti-aging, whitening, and moisturizing of skin, and also does not cause skin irritation.... Agent: Amorepacific Corporation
20140295008 - System and method for time-release of ellagitannins: Disclosed herein are embodiments of compositions that include a plurality of seed particles of various sizes, which may be desirable for providing the time-release of compounds present in the seed particles. By having compositions with seed particles having a range of sizes, various desirable time-release profiles may be generated by... Agent: Nutraberry LLC
20140295009 - Composition and method for boosting immunological response: A method for reducing inflammation at a site of injury in a mammal. A composition with an effective amount of pomegranate extract is administered to a mammal. The pomegranate extract is derived from at least one pomegranate solid and with a higher ratio of higher molecular weight polyphenols than is... Agent:
20140295010 - Skin anti-ageing composition: The invention relates to a skin anti-ageing composition. In particular a skin anti-ageing composition comprising myricetin or glycoside thereof, and at least one LXR alpha agonist. By skin ageing is meant the appearance or manifestation of any one or more of wrinkles or sagging, poor skin barrier such as dryness,... Agent: Conopco, Inc. D/b/a Unilever
20140295011 - Composition containing triticum aestivum lamarck leaf extract or fraction thereof as active ingredient: The present invention relates to a pharmaceutical composition for prevention and treatment of hyperlipidemia or fatty liver disease, the composition containing dichloromethane fractions as an active ingredient amongst fractions obtained by fractionating the alcohol extract of Triticum aestivum Lamarck leaves in an order of dichloromethane, ethyl acetate, and butanol.... Agent: Genematrix Inc.
20140295012 - Latent human immunodeficiency virus reactivation: Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-fB activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-fB activity without a second... Agent:Previous industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20141002:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.
Results in 1.26256 seconds